IFITM proteins inhibit entry driven by the MERS-Coronavirus Spike protein: Evidence for Cholesterol-Independent Mechanisms

Viruses

Volumn 6, Issue 9, 2014, Pages 3683-3698

  Wrensch, Florian ^a   Winkler, Michael ^a   Pöhlmann, Stefan ^a  

^a GERMAN PRIMATE CENTER   (Germany)

Author keywords

Coronavirus; IFITM; MERS; SARS

Indexed keywords

((3Β) 3 [2 (DIETHYLAMINO)ETHOXY]ANDROST 5 EN 17 ONE HYDROCHLORIDE); AGENTS AFFECTING LIPID METABOLISM; CHOLESTEROL; CLOMIFENE; HEMAGGLUTININ; INTERFERON INDUCIBLE TRANSMEMBRANE PROTEIN; INTERFERON INDUCIBLE TRANSMEMBRANE PROTEIN 1; INTERFERON INDUCIBLE TRANSMEMBRANE PROTEIN 2; INTERFERON INDUCIBLE TRANSMEMBRANE PROTEIN 3; MEMBRANE PROTEIN; SMALL INTERFERING RNA; TERCONAZOLE; UNCLASSIFIED DRUG; VIRUS RECEPTOR; VIRUS SPIKE PROTEIN; VIRUS VECTOR; VITRONECTIN; CORONAVIRUS SPIKE GLYCOPROTEIN; DIFFERENTIATION ANTIGEN; IFITM2 PROTEIN, HUMAN; IFITM3 PROTEIN, HUMAN; LEU-13 ANTIGEN; RNA BINDING PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CORONAVIRUS; CYTOTOXICITY; ENDOSOME; FLUORESCENCE MICROSCOPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; INFLUENZA VIRUS; MIDDLE EAST RESPIRATORY SYNDROME; MTT ASSAY; NONHUMAN; PROTEIN EXPRESSION; RESPIRATORY TRACT DISEASE; VIRUS ENTRY; WESTERN BLOTTING; ANIMAL; CELL LINE; CORONAVIRUS INFECTION; GENE EXPRESSION; GENETICS; HEK293 CELL LINE; METABOLISM; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

CORONAVIRUS;

ANIMALS; ANTIGENS, DIFFERENTIATION; BIOLOGICAL TRANSPORT; CELL LINE; CHOLESTEROL; CORONAVIRUS INFECTIONS; GENE EXPRESSION; HEK293 CELLS; HUMANS; MEMBRANE PROTEINS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; RNA-BINDING PROTEINS; SPIKE GLYCOPROTEIN, CORONAVIRUS; VIRUS INTERNALIZATION;

EID: 84908261853     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v6093683     Document Type: Article

References (47)

1. Holmes, K.V. Coronaviruses. In Fields Virology; Knipe, D., Ed.; Lippincott Wiliams & Wilkins: Philadelphia, PA, USA, 2001.
2. Wevers, B.A.; van der Hoek, L. Recently discovered human coronaviruses. Clin. Lab. Med. 2009, 29, 715-724.
3. Chiu, S.S.; Chan, K.H.; Chu, K.W.; Kwan, S.W.; Guan, Y.; Poon, L.L.; Peiris, J.S. Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China. Clin. Infect. Dis. 2005, 40, 1721-1729.
4. Gorse, G.J.; O’Connor, T.Z.; Hall, S.L.; Vitale, J.N.; Nichol, K.L. Human coronavirus and acute respiratory illness in older adults with chronic obstructive pulmonary disease. J. Infect. Dis. 2009, 199, 847-857.
5. Jean, A.; Quach, C.; Yung, A.; Semret, M. Severity and Outcome Associated with Human Coronavirus OC43 Infections among Children. Pediatr. Infect. Dis. J. 2013, 32, 325-329.
6. Jevsnik, M.; Ursic, T.; Zigon, N.; Lusa, L.; Krivec, U.; Petrovec, M. Coronavirus infections in hospitalized pediatric patients with acute respiratory tract disease. BMC Infect. Dis. 2012, 12, doi:10.1186/1471-2334-12-365.
7. Van der Hoek, L.; Sure, K.; Ihorst, G.; Stang, A.; Pyrc, K.; Jebbink, M.F.; Petersen, G.; Forster, J.; Berkhout, B., et al. Croup is associated with the novel coronavirus NL63. PLoS Med. 2005, 2, doi:10.1371/journal.pmed.0020240.
8. Woo, P.C.; Lau, S.K.; Tsoi, H.W.; Huang, Y.; Poon, R.W.; Chu, C.M.; Lee, R.A.; Luk, W.K.; Wong, G.K.; Wong, B.H., et al. Clinical and molecular epidemiological features of coronavirus HKU1-associated community-acquired pneumonia. J. Infect. Dis. 2005, 192, 1898-1907.
9. Graham, R.L.; Donaldson, E.F.; Baric, R.S. A decade after SARS: Strategies for controlling emerging coronaviruses. Nat. Rev. Microbiol. 2013, 11, 836-848.
10. Peiris, J.S.; Guan, Y.; Yuen, K.Y. Severe acute respiratory syndrome. Nat. Med. 2004, 10, S88-S97.
11. Stadler, K.; Rappuoli, R. SARS: Understanding the virus and development of rational therapy. Curr. Mol. Med. 2005, 5, 677-697.
12. WHO. Summary of Probable SARS Cases with Onset of Illness from 1 November 2002 to 31 July 2003; WHO: Geneva, Switzerland, 2014.
13. WHO. Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-Update; WHO: Geneva, Switzerland, 2014.
14. Brass, A.L.; Huang, I.C.; Benita, Y.; John, S.P.; Krishnan, M.N.; Feeley, E.M.; Ryan, B.J.; Weyer, J.L.; van der Weyden, L.; Fikrig, E., et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 2009, 139, 1243-1254.
15. Perreira, J.M.; Chin, C.R.; Feeley, E.M.; Brass, A.L. IFITMs restrict the replication of multiple pathogenic viruses. J. Mol. Biol. 2013, 425, 4937-4955.
16. Schoggins, J.W.; Wilson, S.J.; Panis, M.; Murphy, M.Y.; Jones, C.T.; Bieniasz, P.; Rice, C.M. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011, 472, 481-485.
17. Bertram, S.; Dijkman, R.; Habjan, M.; Heurich, A.; Gierer, S.; Glowacka, I.; Welsch, K.; Winkler, M.; Schneider, H.; Hofmann-Winkler, H., et al. TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium. J. Virol. 2013, 87, 6150-6160.
18. Huang, I.C.; Bailey, C.C.; Weyer, J.L.; Radoshitzky, S.R.; Becker, M.M.; Chiang, J.J.; Brass, A.L.; Ahmed, A.A.; Chi, X.; Dong, L., et al. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog. 2011, 7, e1001258.
19. Feeley, E.M.; Sims, J.S.; John, S.P.; Chin, C.R.; Pertel, T.; Chen, L.M.; Gaiha, G.D.; Ryan, B.J.; Donis, R.O.; Elledge, S.J., et al. IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog. 2011, 7, e1002337.
20. Li, K.; Markosyan, R.M.; Zheng, Y.M.; Golfetto, O.; Bungart, B.; Li, M.; Ding, S.; He, Y.; Liang, C.; Lee, J.C., et al. IFITM proteins restrict viral membrane hemifusion. PLoS Pathog. 2013, 9, e1003124.
21. Desai, T.M.; Marin, M.; Chin, C.R.; Savidis, G.; Brass, A.L.; Melikyan, G.B. IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following virus-endosome hemifusion. PLoS Pathog. 2014, 10, e1004048.
22. Amini-Bavil-Olyaee, S.; Choi, Y.J.; Lee, J.H.; Shi, M.; Huang, I.C.; Farzan, M.; Jung, J.U. The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host. Microbe 2013, 13, 452-464.
23. Bailey, C.C.; Huang, I.C.; Kam, C.; Farzan, M. Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog. 2012, 8, e1002909.
24. Everitt, A.R.; Clare, S.; Pertel, T.; John, S.P.; Wash, R.S.; Smith, S.E.; Chin, C.R.; Feeley, E.M.; Sims, J.S.; Adams, D.J., et al. IFITM3 restricts the morbidity and mortality associated with influenza. Nature 2012, 484, 519-523.
25. Everitt, A.R.; Clare, S.; McDonald, J.U.; Kane, L.; Harcourt, K.; Ahras, M.; Lall, A.; Hale, C.; Rodgers, A.; Young, D.B., et al. Defining the range of pathogens susceptible to Ifitm3 restriction using a knockout mouse model. PLoS One 2013, 8, e80723.
26. Mills, T.C.; Rautanen, A.; Elliott, K.S.; Parks, T.; Naranbhai, V.; Ieven, M.M.; Butler, C.C.; Little, P.; Verheij, T.; Garrard, C.S., et al. IFITM3 and susceptibility to respiratory viral infections in the community. J. Infect. Dis. 2013, 209, 1028-1031.
27. Cenedella, R.J. Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes. Lipids 2009, 44, 477-487.
28. Carette, J.E.; Raaben, M.; Wong, A.C.; Herbert, A.S.; Obernosterer, G.; Mulherkar, N.; Kuehne, A.I.; Kranzusch, P.J.; Griffin, A.M.; Ruthel, G., et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 2011, doi:10.1038/nature10348.
29. Shoemaker, C.J.; Schornberg, K.L.; Delos, S.E.; Scully, C.; Pajouhesh, H.; Olinger, G.G.; Johansen, L.M.; White, J.M. Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection. PLoS One 2013, 8, e56265.
30. Zhao, X.; Guo, F.; Liu, F.; Cuconati, A.; Chang, J.; Block, T.M.; Guo, J.T. Interferon induction of IFITM proteins promotes infection by human coronavirus OC43. Proc. Natl. Acad. Sci. USA 2014, 111, 6756-6761.
31. Warren, C.J.; Griffin, L.M.; Little, A.S.; Huang, I.C.; Farzan, M.; Pyeon, D. The antiviral restriction factors IFITM1, 2 and 3 do not inhibit infection of human papillomavirus, cytomegalovirus and adenovirus. PLoS One 2014, 9, e96579.
32. Eckert, N.; Wrensch, F.; Gartner, S.; Palanisamy, N.; Goedecke, U.; Jager, N.; Pöhlmann, S.; Winkler, M. Influenza a virus encoding secreted gaussia luciferase as useful tool to analyze viral replication and its inhibition by antiviral compounds and cellular proteins. PLoS One 2014, 9, e97695.
33. Musiol, A.; Gran, S.; Ehrhardt, C.; Ludwig, S.; Grewal, T.; Gerke, V.; Rescher, U. Annexin A6-balanced late endosomal cholesterol controls influenza a replication and propagation. MBio 2013, 4, e00608-e00613.
34. Lin, T.Y.; Chin, C.R.; Everitt, A.R.; Clare, S.; Perreira, J.M.; Savidis, G.; Aker, A.M.; John, S.P.; Sarlah, D.; Carreira, E.M., et al. Amphotericin B increases influenza A virus infection by preventing IFITM3-mediated restriction. Cell Rep. 2013, 5, 895-908.
35. Lafourcade, C.; Sobo, K.; Kieffer-Jaquinod, S.; Garin, J.; van der Goot, F.G. Regulation of the V-ATPase along the endocytic pathway occurs through reversible subunit association and membrane localization. PLoS One 2008, 3, e2758.
36. John, S.P.; Chin, C.R.; Perreira, J.M.; Feeley, E.M.; Aker, A.M.; Savidis, G.; Smith, S.E.; Elia, A.E.; Everitt, A.R.; Vora, M., et al. The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication. J. Virol. 2013, 87, 7837-7852.
37. Chaipan, C.; Kobasa, D.; Bertram, S.; Glowacka, I.; Steffen, I.; Tsegaye, T.S.; Takeda, M.; Bugge, T.H.; Kim, S.; Park, Y., et al. Proteolytic activation of the 1918 influenza virus hemagglutinin. J. Virol. 2009, 83, 3200-3211.
38. Gierer, S.; Bertram, S.; Kaup, F.; Wrensch, F.; Heurich, A.; Kramer-Kuhl, A.; Welsch, K.; Winkler, M.; Meyer, B.; Drosten, C., et al. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J. Virol. 2013, 87, 5502-5511.
39. Hofmann, H.; Hattermann, K.; Marzi, A.; Gramberg, T.; Geier, M.; Krumbiegel, M.; Kuate, S.; Uberla, K.; Niedrig, M., et al. S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J. Virol. 2004, 78, 6134-6142.
40. Hofmann, H.; Pyrc, K.; van der Hoek, L.; Geier, M.; Berkhout, B.; Pöhlmann, S. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc. Natl. Acad. Sci. USA 2005, 102, 7988-7993.
41. Simmons, G.; Reeves, J.D.; Grogan, C.C.; Vandenberghe, L.H.; Baribaud, F.; Whitbeck, J.C.; Burke, E.; Buchmeier, M.J.; Soilleux, E.J., et al. DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology 2003, 305, 115-123.
42. Raj, V.S.; Mou, H.; Smits, S.L.; Dekkers, D.H.; Muller, M.A.; Dijkman, R.; Muth, D.; Demmers, J.A.; Zaki, A.; Fouchier, R.A., et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013, 495, 251-254.
43. Bartosch, B.; Dubuisson, J.; Cosset, F.L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 2003, 197, 633-642.
44. Malim, M.H.; McCarn, D.F.; Tiley, L.S.; Cullen, B.R. Mutational definition of the human immunodeficiency virus type 1 Rev activation domain. J. Virol. 1991, 65, 4248-4254.
45. Evan, G.I.; Lewis, G.K.; Ramsay, G.; Bishop, J.M. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol. Cell Biol. 1985, 5, 3610-3616.
46. O’Doherty, U.; Swiggard, W.J.; Malim, M.H. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol. 2000, 74, 10074-10080.
47. Kupcsik, L. Estimation of cell number based on metabolic activity: The MTT reduction assay. Methods Mol. Biol. 2011, 740, 13-19.